Reviewing Climb Bio (CLYM) and Its Peers

Climb Bio (NASDAQ:CLYM) is one of 1,060 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its competitors? We will compare Climb Bio to related companies based on the strength of its profitability, valuation, dividends, risk, institutional ownership, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Climb Bio and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	0	0	1	1	3.50
Climb Bio Competitors	7834	21289	48948	1243	2.55

Climb Bio presently has a consensus target price of $10.00, indicating a potential upside of 344.44%. As a group, “Pharmaceutical preparations” companies have a potential upside of 186.11%. Given Climb Bio’s stronger consensus rating and higher probable upside, research analysts clearly believe Climb Bio is more favorable than its competitors.

Profitability

This table compares Climb Bio and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-42.21%	-41.39%
Climb Bio Competitors	-3,590.11%	-276.96%	-39.10%

Volatility & Risk

Climb Bio has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Climb Bio’s competitors have a beta of 3.70, suggesting that their average share price is 270% more volatile than the S&P 500.

Institutional and Insider Ownership

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 3.2% of Climb Bio shares are owned by insiders. Comparatively, 13.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Climb Bio and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Climb Bio	N/A	-$35.12 million	-1.06
Climb Bio Competitors	$9.58 billion	$147.90 million	-5.54

Climb Bio’s competitors have higher revenue and earnings than Climb Bio. Climb Bio is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Climb Bio beats its competitors on 7 of the 13 factors compared.

Climb Bio Company Profile

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.